{"id":"semaglutide-rybelsus","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Nausea"},{"rate":"5–15%","effect":"Vomiting"},{"rate":"20–30%","effect":"Diarrhea"},{"rate":"15–25%","effect":"Constipation"},{"rate":"10–20%","effect":"Abdominal pain"},{"rate":"5–10%","effect":"Headache"},{"rate":"variable","effect":"Hypoglycemia (when combined with insulin or sulfonylureas)"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. By binding to GLP-1 receptors on pancreatic beta cells, it stimulates glucose-dependent insulin secretion and inhibits glucagon release. Additionally, it slows gastric emptying and acts on central appetite centers, reducing hunger and caloric intake.","oneSentence":"Semaglutide activates GLP-1 receptors to increase insulin secretion, decrease glucagon release, and slow gastric emptying, thereby lowering blood glucose and promoting weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:19.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT07221214","phase":"PHASE2","title":"GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-03-31","conditions":"HIV, Alcohol, Smoking Cigarette","enrollment":200},{"nctId":"NCT07401992","phase":"PHASE4","title":"Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-01-15","conditions":"Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2","enrollment":62},{"nctId":"NCT07295223","phase":"PHASE3","title":"Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-12-30","conditions":"Acute Myocardial Infarction With ST Elevation","enrollment":44},{"nctId":"NCT07297589","phase":"PHASE3","title":"Epicardial Cardiac Fat-CT (EPIC-CT)","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-12-30","conditions":"STEMI - ST Elevation Myocardial Infarction, Epicardial Fat","enrollment":136},{"nctId":"NCT06338553","phase":"EARLY_PHASE1","title":"GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-12","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT05714683","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-12-31","conditions":"Diabetes Mellitus, Type 2","enrollment":600},{"nctId":"NCT05035082","phase":"PHASE4","title":"A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-09-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1020},{"nctId":"NCT06827002","phase":"PHASE1, PHASE2","title":"Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Yaounde 1","startDate":"2023-02-12","conditions":"Obesity and Overweight, Appetite Regulation","enrollment":248},{"nctId":"NCT07200622","phase":"PHASE2","title":"Oral Semaglutide in Patients With Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-09-25","conditions":"Alzheimer Disease","enrollment":60},{"nctId":"NCT07179120","phase":"PHASE2","title":"Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-05-01","conditions":"Obesity-related Male Infertility","enrollment":180},{"nctId":"NCT07135245","phase":"PHASE2","title":"Improved Treatment and Monitoring of Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Rune Skovgaard Rasmussen","startDate":"2026-01-01","conditions":"Alzheimer Disease (AD)","enrollment":180},{"nctId":"NCT04572165","phase":"","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","status":"UNKNOWN","sponsor":"Novo Nordisk A/S","startDate":"2021-01-26","conditions":"Diabetes Mellitus, Type 2","enrollment":600000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["semaglutide"],"phase":"marketed","status":"active","brandName":"Semaglutide (Rybelsus®)","genericName":"Semaglutide (Rybelsus®)","companyName":"Instituto Mexicano del Seguro Social","companyId":"instituto-mexicano-del-seguro-social","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide activates GLP-1 receptors to increase insulin secretion, decrease glucagon release, and slow gastric emptying, thereby lowering blood glucose and promoting weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}